MDM2 and cancer: At present, although the potential resistance mechanisms of cancer immunotherapy and HPD are not yet clear, studies have shown that MDM2 over expression is highly correlated with poor prognosis and may even lead to the development of HPD (PMID: 33334611; PMID: 27827313; PMID: 30193240; PMID: 28351930).